

Creating & Developing Companies To Improve the Human Condition

Trendlines

Medical • Agtech • Labs

Post-IPO Update

Steve Rhodes, Chairman & CEO
Todd Dollinger, Chairman & CEO

December 2016

IPO Singapore (26 November 2015)

Successful offering, reasonable valuation

- Placement of 75.8 million shares at S$0.33
- Gross proceeds raised of S$25 million
- Total capital raised approximately S$38.7 million (includes S$13.7 million from pre-IPO investors)
- B.Braun Melsungen entered as cornerstone investor with investment of S$7.1 million

Renewal of OCS License(s)

- Renewed Trendlines Medical license
- Trendlines received OCS (Office of the Chief Scientist) approval to operate Trendlines Agtech and Trendlines Medical under a single license in our headquarters facility
- Today operate both incubators under a single license in a single facility yielding significant benefits, including
  - More direct support from Group's professional support team: business development, R&D, finance, etc.
  - Efficiencies of scale

Corporate Financial Developments

- Trendlines completed **exit** of portfolio company E.T.View Medical for net proceeds of US$ 3.6 million
- Trendlines received US$ 0.9 million **dividend** from the Most Valuable Portfolio Company in Q3 2016 – increased cash balance, but no impact on earnings
- More than doubled **Trendlines Labs** revenue from US$ 384,000 in the 9 months through 30.9.15 to US$ 832,000 in the 9 months through 30.9.16
- Total **current assets** were US$ 20.4 million on 30 September 2016, compared to US$ 18.7 million on 30 June 2016, and US$ 24.0 million on 31 December 2015

Earnings Results as of 30 September 2016

- Q3 2016 vs Q3 2015
  - Total income was US$ 4.1 million in Q3 2016, compared to loss of US$ 0.2 million in Q3 2015
  - Net income totaled US$ 1.6 million in Q3 2016 vs loss of US$ 3.4 million in Q3 2015
- First 9 months of 2016 vs first 9 months of 2015
  - Total income of US$ 2.3 million for first 9 months 2016, compared to total income of US$ 8.8 million for the first 9 months of 2015
  - Net loss of US$ 3.8 million first 9 months 2016 , compared to net loss of US$ 0.04 million in the first 9 months of 2015

Major Corporate Partnerships: B. Braun Melsungen AG

- B. Braun is one of the world's largest privately owned medical device distributor with global sales of € 6.12 billion
- B. Braun invested S$ 7.1 million as cornerstone investor in listing of Trendlines on the SGX
- B. Braun signed definitive agreement for co-investment in Trendlines Medical Singapore and commits to support the portfolio companies in technological development, regulatory, medical, scientific affairs, and marketing and sales
- B. Braun closed investments in Portfolio Companies: Gordian Surgical and ApiFix
- B. Braun doing projects with Trendlines Labs

Major Corporate Partnerships: Bayer AG

- Bayer AG is a public company (market cap € 73.5 billion) with global sales of € 46.3 billion
- Bayer Crop Science announced a partnership with Trendlines to invest in agricultural technologies through the establishment of the *Bayer Trendlines Ag Innovation Fund*. The partnership agreement includes a US$ 10 million investment from Bayer
- Head of R&D at Bayer Crop Science gave the keynote speech at Trendlines' AgriVest Conference to investors and experts from 20 countries, including investors, brokers, analysts and journalists from Singapore

Major Corporate Partnerships: Japanese Medical Device MNC

- Trendlines Labs partners with major multinational medical device corporation (MNC) headquartered in Japan.
- Japanese MNC signed an agreement with Trendlines Labs to collaborate on clinical opportunities in agreed fields
- Trendlines Labs to develop innovative medical device products for manufacture and marketing by the Japanese MNC.
- Current status
  - Three investigation projects
  - One proof of concept
  - One development project started by Japanese MNC

Major Corporate Partnerships: U.S. Medical Device MNC

- Trendlines Labs partners with major U.S. multinational medical device manufacturer
- One product successfully introduced to market (LithoVue™ ureteroscope)
- One project completed proof of concept
- One investigation (Endo division)
- Additional projects under discussion

Expansion of Operations into New Markets

- **Trendlines** establishes **Trendlines Medical Singapore**, the first medical incubator established by an Israeli company in Singapore and Trendlines' first incubator outside of Israel
- **Eric Loh** appointed CEO, Trendlines Medical Singapore
- **B. Braun** signs definitive investment and cooperation agreement relative to Trendlines Medical Singapore

Select Trendlines Medical Portfolio Company Milestones

- ApiFix exceeds 100-patient milestone and Eran Feldhay named CEO
- Gordian Surgical receives CE Mark
- CoreBone receives CE Mark and ISO
- OrthoSpin starts FIM trials
- LapSpace performs ~200 cases; sells approximately 150 devices
- Leviticus Cardio partners with two major MNCs

Select Trendlines AgTech Portfolio Company Milestones

- EdenShield receives US patent for its nontoxic pest control solution, reaches sales of ~ US$ 220,000
- ViAqua achieves excellent test results in US & Thailand
- AquiNovo is in negotiation with a strategic partner
- BioFishency reaches sales of ~US$ 500,000; units installed in Israel, India, Philippines, Bangladesh, and other countries

Follow-on funding for Portfolio companies

- Magdent
- EdenShield
- Hargol
- Leviticus
- Saturas
- CoreBone
- VivoText
- Liola
- Advanced Memtech

- Breezy
- GreenSpense
- Gordian
- ApiFix
- ProArc
- Arcuro*
- OMEQ Medical
- Vensica*

*First round

Portfolio Expansion: 8 New Companies

Tandem Technologies
Zeev Implants
OB Smart
Hargol FoodTech
AquiNovo
InPlant Technologies
CorAlert
MetoMotion

Trendlines Labs

- Two development programs with new strategic partners
- Three new strategic, revenue-producing agreements
- Two Trendlines Labs' technologies entering commercialization stage:
  - EUS FNA Biopsy Needles (incubator company in process)
  - Stress Urinary Incontinence (SIIRD with Singapore partner)

Keeping Our Promises to Investors

Since our listing in November 2015

Our Goals	What We Did
1. Renew licenses from Israeli gov't.	Renewed one license and merged second into it
2. Start new companies	Started 9 new companies
3. Establish new incubator	Established Trendlines Medical Singapore
4. Grow Trendlines Labs	Revenue has doubled, new strategic partners and projects
5. Expand strategic relationships	Bayer investing US$ 10 million, B. Braun investing in Singapore incubator, Japanese partner
6. Raise follow-on capital	17 companies have raised
7. Achieve exits	Sold E.T.View Medical, generated US$ 3.6 million in cash

All Promises Kept

Building a Strong Investor Base

- Judith Kleinman named Director of Investor Relations & Corporate Communications
  - 10 years investment banking: analyst & institutional sales
  - 15 years investor relations: consultant & in-house
- Active IR schedule: Asia & North America
  - Conferences
  - Non-deal roadshows
  - Portfolio company roadshows
  - Focus on news flow
- Created ADR program in USA to facilitate trading for N. American investors and raise visibility of The Trendlines Group worldwide
  - Converting pre-IPO holdings of shareholders in N. America to ADRs
  - Received FINRA approval for trading on OTCQX International (31 Aug 2016)

Creating & Developing Companies To Improve the Human Condition

Trendlines
Medical · Agtech · Labs

+972.72.260.7000 | www.trendlines.com

Todd Dollinger, Chairman & CEO
Steve Rhodes, Chairman & CEO

Judith Kleinman, Director
Investor Relations & Corporate Communications
judith@trendlines.com

December 2016